NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

Under the terms of the settlement, the firms will cross-license patents related to microfluidic cellular analysis.

Cellectricon and Fluxion said they will ask the US District Court for the Northern District of California to dismiss all claims that Cellectricon brought against Fluxion involving US Patent Nos. 7,390,650; 7,470,518; and 7,563,614.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.